Indicators

Category

HR (95% CI)

p-value

Overall Survival

Months

%

Adenocarcinoma

Imidazole compounds, mmol/l

˂0.311

1

0.00014

29.1

33.4

>0.311

3.14 (1.59–6.09)^*

18.2

16.4

Seromucoids, c.u.

>0.098

1

0.02320

27.1

33.1

˂0.098

2.34 (1.22–4.43)^*

16.5

9.9

Uric acid, nmol/ml

>83

1

0.00633

27.1

40.1

˂83

2.27 (1.24–4.12)^*

17.9

20.6

IC + Seromucoids + Uric acid

Favorable prognosis

1

0.00004

36.2

48.6

Other combinations

2.92 (1.04-8.10)^*

21.3

21.8

Unfavorable prognosis

7.91 (2.52–24.11)^*

14.2

7.0

Lung neuroendocrine tumors

Urea, mmol/l

>8

1

0.15670

22.0

33.2

˂8

1.63 (0.59-4.43)

11.2

21.8

NO, nmol/ml

>24

1

0.08330

21.1

32.7

˂24

2.71 (0.90-8.02)

11.2

18.3

ALP, U/l

>74

1

0.00555

26.0

43.8

˂74

4.93 (1.55-15.33)^*

9.7

-

Urea + NO + ALP

Favorable prognosis

1

0.01184

33.5

67.9

Other combinations

1.81 (0.19-16.62)

13.1

19.4

Unfavorable prognosis

12.50 (1.09-138.71)^*

6.5

-

Prognostic saliva values depending on the type of treatment

Radical treatment

LDH, U/l

>1748

1

0.00968

38.5

68.2

545-1748

2.54 (0.83-7.71)

36.7

41.7

˂545

7.20 (2.13-23.70)^*

28.7

20.8

Combined treatment

NO, nmol/ml

>42

1

0.02797

31.1

56.9

15-42

3.97 (1.55-9.94)^*

24.8

21.0

˂15

5.64 (1.89-16.46)^*

23.8

14.2

Palliative treatment

Imidazole compounds, mmol/l

˂0.311

1

0.01114

14.8

4.8

>0.311

1.08 (0.22-5.20)

10.1

0.26

NO, nmol/ml

˂24

1

0.10560

12.5

2.9

>24

1.32 (0.37-4.67)

10.7

0.53

IC + NO

Favorable prognosis

1

0.01827

16.6

6.8

Unfavorable prognosis

2.73 (1.07-12.92)^*

11.0

-